The Gomu Gomu no Mi, also known by its true name of the Hito Hito no Mi, Model: Nika, is a Devil Fruit full of mysteries, and one that is quite easily the most important in the entire One Piece story.

Usually, the screen is the biggest power hog on smartwatches and fitness trackers. The Mi Band 7 is no exception. Disable all-day blood oxygen monitoring. The Mi Band 7 is the first in the series ...

"We want to move forward, not backwards," Mackle said. "There is no point in sitting back and getting comfortable with the status quo." Kaikōura's youngest sitting councillor, Vicki Gulleford, joined ...

Looking for something to replace or complement your Koyfin subscription? Here’s a breakdown of some stellar alternatives, each offering a unique set of tools. Benzinga Pro is a powerful real ...

The Gomu Gomu no Mi, rarely known by its real name of the Hito Hito no Mi, Model: Nika, is a legendary Devil Fruit in the One Piece world. Although it was believed to be a rather ordinary Devil ...

Want to keep track of the largest startup funding deals in 2025 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a ...

Startup Eikon Therapeutics raised one of the biggest biotech rounds thus far in this young year. The Hayward, California-based drug startup closed on nearly $351 million in a Series D from the likes ...

One of biotech’s best-fund­ed star­tups has just raised a huge new round to take its lead drug in­to fi­nal-stage test­ing.

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Eikon Therapeutics, a well-funded drug startup run by Merck & Co.’s former research chief, has raised ...

The upward trajectory continues for Eikon Therapeutics, which announced that it has raised $351 million to fund various cancer related clinical trials. The Series D funding unveiled Wednesday morning ...

Eikon’s lead candidate, EIK1001, is being tested for advanced melanoma. The candidate is currently in late-stage development, which the biotech will fund using Wednesday’s series D raise. Eikon ...

now Eikon’s chief medical officer, and Mike Klobuchar, its chief operating officer. Ampersand, a buzzy biotech formed by Flagship Pioneering, raised $65 million in new funding from investors that ...